Varian Medical Systems, Inc. (VAR) Shares Bought by Vident Investment Advisory LLC

Vident Investment Advisory LLC lifted its stake in shares of Varian Medical Systems, Inc. (NYSE:VAR) by 74.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 128,154 shares of the medical equipment provider’s stock after buying an additional 54,897 shares during the quarter. Vident Investment Advisory LLC owned approximately 0.14% of Varian Medical Systems worth $12,823,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Chevy Chase Trust Holdings Inc. boosted its holdings in Varian Medical Systems by 1.1% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 80,104 shares of the medical equipment provider’s stock valued at $8,015,000 after purchasing an additional 876 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Varian Medical Systems in the third quarter valued at approximately $24,607,000. First Republic Investment Management Inc. boosted its holdings in Varian Medical Systems by 38.8% in the third quarter. First Republic Investment Management Inc. now owns 5,110 shares of the medical equipment provider’s stock valued at $512,000 after purchasing an additional 1,429 shares in the last quarter. Magnetar Financial LLC boosted its holdings in Varian Medical Systems by 72.3% in the third quarter. Magnetar Financial LLC now owns 44,968 shares of the medical equipment provider’s stock valued at $4,499,000 after purchasing an additional 18,872 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its holdings in Varian Medical Systems by 3.5% in the third quarter. Asset Management One Co. Ltd. now owns 264,344 shares of the medical equipment provider’s stock valued at $26,445,000 after purchasing an additional 8,958 shares in the last quarter. 99.15% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on the company. BTIG Research downgraded Varian Medical Systems from a “buy” rating to a “neutral” rating in a report on Thursday, September 7th. They noted that the move was a valuation call. Citigroup upped their price target on Varian Medical Systems from $119.00 to $121.00 and gave the company a “neutral” rating in a report on Monday, October 30th. Royal Bank of Canada set a $105.00 price objective on Varian Medical Systems and gave the company a “hold” rating in a report on Thursday, November 30th. Robert W. Baird reissued a “hold” rating and issued a $99.00 price objective on shares of Varian Medical Systems in a report on Monday, August 28th. Finally, Zacks Investment Research downgraded Varian Medical Systems from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. Varian Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $98.39.

Varian Medical Systems, Inc. (NYSE:VAR) traded up $2.10 during mid-day trading on Friday, hitting $111.87. The stock had a trading volume of 883,273 shares, compared to its average volume of 645,538. Varian Medical Systems, Inc. has a 1-year low of $75.54 and a 1-year high of $114.09. The firm has a market capitalization of $10,249.19, a P/E ratio of 29.67, a P/E/G ratio of 3.29 and a beta of 0.67.

Varian Medical Systems (NYSE:VAR) last released its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $1.09 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.19 by ($0.10). Varian Medical Systems had a return on equity of 23.68% and a net margin of 8.85%. The company had revenue of $739.00 million for the quarter, compared to analysts’ expectations of $741.69 million. During the same quarter last year, the company earned $1.03 EPS. Varian Medical Systems’s revenue for the quarter was down 1.1% compared to the same quarter last year. equities analysts anticipate that Varian Medical Systems, Inc. will post 4.25 earnings per share for the current fiscal year.

In other news, insider Dow R. Wilson sold 15,059 shares of the company’s stock in a transaction that occurred on Friday, October 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,542,041.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Andrew Eckert sold 5,651 shares of the stock in a transaction on Friday, October 6th. The stock was sold at an average price of $102.39, for a total value of $578,605.89. The disclosure for this sale can be found here. Insiders have sold 26,768 shares of company stock valued at $2,771,819 in the last 90 days. Company insiders own 0.91% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/17/vident-investment-advisory-llc-boosts-holdings-in-varian-medical-systems-inc-var.html.

About Varian Medical Systems

Varian Medical Systems, Inc is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy.

Institutional Ownership by Quarter for Varian Medical Systems (NYSE:VAR)

Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply